keyword
MENU ▼
Read by QxMD icon Read
search

Varenicline

keyword
https://www.readbyqxmd.com/read/28207744/utilization-of-smoking-cessation-medication-benefits-among-medicaid-fee-for-service-enrollees-1999-2008
#1
Jennifer Kahende, Ann Malarcher, Lucinda England, Lei Zhang, Paul Mowery, Xin Xu, Varadan Sevilimedu, Italia Rolle
OBJECTIVE: To assess state coverage and utilization of Medicaid smoking cessation medication benefits among fee-for-service enrollees who smoked cigarettes. METHODS: We used the linked National Health Interview Survey (survey years 1995, 1997-2005) and the Medicaid Analytic eXtract files (1999-2008) to assess utilization of smoking cessation medication benefits among 5,982 cigarette smokers aged 18-64 years enrolled in Medicaid fee-for-service whose state Medicaid insurance covered at least one cessation medication...
2017: PloS One
https://www.readbyqxmd.com/read/28202387/varenicline-enhances-oxidized-ldl-uptake-by-increasing-expression-of-lox-1-and-cd36-scavenger-receptors-through-%C3%AE-7-nachr-in-macrophages
#2
Yuki Kanaoka, Mitsuhisa Koga, Keita Sugiyama, Kaoru Ohishi, Yasufumi Kataoka, Atsushi Yamauchi
Varenicline is a widely used and effective drug for smoking cessation. It is a partial agonist of the α4β2 nicotinic acetylcholine receptor (nAChR) and full agonist of α7 nAChR. We have reported that varenicline aggravates formation of atherosclerotic plaques through α7 nAChR in apolipoprotein E knockout mice. However, little is known about its effects on macrophages in atherosclerotic plaques. Here, we ascertained whether varenicline promotes oxidized low-density lipoprotein (oxLDL) uptake in mouse peritoneal macrophages in vitro and clarified its mechanism...
February 12, 2017: Toxicology
https://www.readbyqxmd.com/read/28185963/increased-network-centrality-as-markers-of-relapse-risk-in-nicotine-dependent-individuals-treated-with-varenicline
#3
Zhujing Shen, Peiyu Huang, Chao Wang, Wei Qian, Yihong Yang, Minming Zhang
Identifying smokers at high risk of relapse could improve the effectiveness of cessation therapies. Although altered regional brain function in smokers has been reported, whether the whole-brain functional organization differs smokers with relapse vulnerability from others remains unclear. Thus, the goal of this study is to investigate the baseline functional connectivity differences between relapsers and quitters. Using resting-state fMRI, we acquired images from 57 smokers prior to quitting attempts. After 12-week treatment with varenicline, smokers were divided into relapsers (n=36) and quitters (n=21) (quitter: continuously abstinent for weeks 9-12)...
February 6, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28182446/factor-structure-of-the-smoking-cessation-self-efficacy-questionnaire-among-smokers-with-and-without-a-psychiatric-diagnosis
#4
Matthew Clyde, Andrew Pipe, Charl Els, Robert Reid, Heather Tulloch
Cessation self-efficacy has been shown to be a consistent predictor of smoking cessation outcomes. To date, no scale assessing cessation self-efficacy has been validated across smokers with and without a psychiatric diagnosis (current or past). Smokers with a psychiatric diagnosis are typically heavy smokers, have a more difficult time quitting, and are more prone to experience lower self-efficacy. Determining whether smoking cessation self-efficacy scores are invariant across these populations is crucial for future research and intervention strategies...
February 9, 2017: Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors
https://www.readbyqxmd.com/read/28168609/a-comparison-of-the-characteristics-of-ios-and-android-users-of-a-smoking-cessation-app
#5
Harveen Kaur Ubhi, Daniel Kotz, Susan Michie, Onno C P van Schayck, Robert West
iOS and Android smartphone users may differ in ways that affect their use and likelihood of success when using a smoking cessation application (app). If so, it may be necessary to take the device type (iOS and Android) into account when designing smoking cessation apps and in studies evaluating app effectiveness. How do socio-demographic and smoking characteristics, potentially relevant to engagement and cessation outcomes, of the SF28 app users differ between those using the iOS version and those using the Android version? Data were collected between October 2013 and April 2015...
February 6, 2017: Translational Behavioral Medicine
https://www.readbyqxmd.com/read/28167895/a-comparison-of-the-efficacy-of-varenicline-and-bupropion-and-an-evaluation-of-the-effect-of-the-medications-in-the-context-of-the-smoking-cessation-programme
#6
Ali Ramazan Benli, Selman Erturhan, Muhammet Ali Oruc, Pinar Kalpakci, Didem Sunay, Yeltekin Demirel
BACKGROUND: Within the context of the support program for smoking cessation, initiated by the Turkish Ministry of Health in 2011, those who present at 'smoking cessation' centres and are found to be suitable for pharmacological treatment are given varenicline and bupropion free of charge. As the smoking cessation programme is centralized, the selection of the medication is made randomly to provide a fixed distribution rate. The aim of this study was to evaluate the efficacy of both varenicline and bupropion in smoking cessation and to evaluate the effect of the smoking cessation programme...
2017: Tobacco Induced Diseases
https://www.readbyqxmd.com/read/28120003/pet-imaging-of-%C3%AE-7-nicotinic-acetylcholine-receptors-a-comparative-study-of-18-f-asem-and-18-f-dbt-10-in-nonhuman-primates-and-further-evaluation-of-18-f-asem-in-humans
#7
Ansel T Hillmer, Songye Li, Ming-Qiang Zheng, Matthias Scheunemann, Shu-Fei Lin, Nabeel Nabulsi, Daniel Holden, Richard Pracitto, David Labaree, Jim Ropchan, Rodrigo Teodoro, Winnie Deuther-Conrad, Irina Esterlis, Kelly P Cosgrove, Peter Brust, Richard E Carson, Yiyun Huang
PURPOSE: The α7 nicotinic acetylcholine receptor (nAChR) is implicated in many neuropsychiatric disorders, making it an important target for positron emission tomography (PET) imaging. The first aim of this work was to compare two α7 nAChRs PET radioligands, [(18)F]ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-([(18)F]fluorodibenzo[b,d]thiophene 5,5-dioxide) and [(18)F]DBT-10 (7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-2-([(18)F]fluorodibenzo[b,d]thiophene 5,5-dioxide), in nonhuman primates...
January 24, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28101793/substance-use-disorders-among-patients-with-type-2-diabetes-a-dangerous-but-understudied-combination
#8
REVIEW
Kimberly N Walter, Julie A Wagner, Eda Cengiz, William V Tamborlane, Nancy M Petry
PURPOSE OF REVIEW: This paper reviews research on substance use and disorders (SUDs) among adults with diabetes. It describes epidemiological data on SUDs in persons with type 2 diabetes, overviews effects of substance use on diabetes outcomes, and discusses treatments for SUDs in patients with diabetes. RECENT FINDINGS: Rates of current smoking range from 10 to 26% and alcohol use disorders are 0-5%. Rates of illicit SUDs are 3-4%, but there are no population-based studies using nationally representative samples...
January 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28093398/efficacy-and-safety-of-smoking-cessation-interventions-in-patients-with-cardiovascular-disease-a-network-meta-analysis-of-randomized-controlled-trials
#9
Karine Suissa, Jordan Larivière, Mark J Eisenberg, Maria Eberg, Genevieve C Gore, Roland Grad, Lawrence Joseph, Pauline M Reynier, Kristian B Filion
BACKGROUND: Although the efficacy and safety of smoking cessation interventions are well established, their efficacy and safety in patients with cardiovascular disease (CVD) remain unclear. The objective of this study was to evaluate the efficacy and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a meta-analysis of randomized controlled trials. METHODS AND RESULTS: EMBASE, PsycINFO, MEDLINE, PubMed, and the Cochrane Tobacco Addiction Specialized Register were searched for randomized controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral therapies in CVD patients...
January 2017: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/28087221/varenicline-provokes-impulsive-action-by-stimulating-%C3%AE-4%C3%AE-2-nicotinic-acetylcholine-receptors-in-the-infralimbic-cortex-in-a-nicotine-exposure-status-dependent-manner
#10
Yu Ohmura, Hitomi Sasamori, Iku Tsutsui-Kimura, Takeshi Izumi, Takayuki Yoshida, Mitsuhiro Yoshioka
Higher impulsivity is a risk factor for criminal involvement and drug addiction. Because nicotine administration enhances impulsivity, the effects of stop-smoking aids stimulating nicotinic acetylcholine receptors (nAChRs) on impulsivity must be determined in different conditions. Our goals were 1) to confirm the relationship between varenicline, a stop-smoking aid and α4β2 nAChR partial agonist, and impulsivity, 2) to elucidate the mechanisms underlying the effects of varenicline, 3) to examine whether a low dose of varenicline that does not evoke impulsive action could block the stimulating effects of nicotine on impulsive action, 4) to determine whether the route of administration could modulate the effects of varenicline on impulsive action, and 5) to determine whether the effects of varenicline on impulsivity could be altered by smoking status...
January 10, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28077163/the-efficacy-of-varenicline-in-achieving-abstinence-among-waterpipe-tobacco-smokers-study-protocol-for-a-randomized-controlled-trial
#11
Raana Zahid, Omara Dogar, Sonia Mansoor, Amina Khan, Mona Kanaan, Mohammed Jawad, Jasjit S Ahluwalia, Kamran Siddiqi
BACKGROUND: Waterpipe tobacco smoking has increased among youth across the globe including in the US, and it continues as a common and traditional form of smoking tobacco in Pakistan. A range of behavioral and pharmacological therapies are available to support people in quitting cigarette smoking; however, little evidence exists for the efficacy of these therapies in achieving abstinence among waterpipe tobacco smokers. The objective of this study is to assess the efficacy of varenicline when added to behavioral support for waterpipe tobacco smoking cessation, by measuring biochemically validated continuous abstinence in waterpipe tobacco smokers...
January 11, 2017: Trials
https://www.readbyqxmd.com/read/28055135/a-combination-of-naltrexone%C3%A2-%C3%A2-varenicline-retards-the-expression-of-a-genetic-predisposition-toward-high-alcohol-drinking
#12
Janice C Froehlich, Stephen M Fischer, Emily R Nicholson, Julian E Dilley, Nicholas J Filosa, Teal N Smith, Logan C Rademacher
BACKGROUND: This study examined whether naltrexone (NTX) or varenicline (VAR), alone or in combination, can retard the phenotypic expression of a genetic predisposition toward high alcohol drinking in rats selectively bred for high alcohol intake when drug treatment is initiated prior to, or concomitantly with, the onset of alcohol drinking. METHODS: Alcohol-naïve P rats were treated daily with NTX (15.0 mg/kg BW), VAR (1.0 mg/kg BW), a combination of NTX (15...
January 5, 2017: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/28048167/su-f-i-66-the-effects-of-nicotinic-agonists-on-rat-hippocampal-glutamatergic-fluctuation-by-using-proton-magnetic-resonance-spectroscopy-at-9-4t
#13
S-I Lim, K-H Song, C-H Yoo, D-C Woo, B-Y Choe
PURPOSE: Nicotine exerts its effects through the activation of nicotinic acetylcholine receptors (nAChRs). Varenicline, a smoking cessation aid, is a partial agonist acting at the α4β2 nAChRs. Although nicotine and varenicline contribute to the reward system at the same time, the influence of the substances on hippocampal neurochemical changes has not been investigated yet. We therefore studied the effects of repeated nicotine exposure and varenicline administration on hippocampus of rats by using in vivo proton magnetic resonance spectroscopy (1H MRS) at 9...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28028600/the-contribution-of-%C3%AE-4%C3%AE-2-and-non-%C3%AE-4%C3%AE-2-nicotinic-acetylcholine-receptors-to-the-discriminative-stimulus-effects-of-nicotine-and-varenicline-in-mice
#14
Fernando B de Moura, Lance R McMahon
RATIONALE: The extent to which non-α4β2 versus α4β2* nAChRs contribute to the behavioral effects of varenicline and other nAChR agonists is unclear. OBJECTIVES: The purpose of this study was to characterize the discriminative stimulus effects of varenicline and nicotine using various nAChR agonists and antagonists to elucidate possible non-α4β2 nAChR mechanisms. METHODS: Separate groups of male C57BL/6J mice were trained to discriminate varenicline (3...
March 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28025093/varenicline-improves-motor-and-cognitive-deficits-and-decreases-depressive-like-behaviour-in-late-stage-yac128-mice
#15
Ailsa L McGregor, Gary D'Souza, Donghyo Kim, Malcolm D Tingle
OBJECTIVE: Studies in the post mortem human brain and in genetic mouse model suggest that dysfunctional cholinergic neurotransmission, through a loss of agonist rather than receptors may be a significant contributing factor to HD pathology. If correct, pharmacological replacement may therefore be a potential treatment strategy. We have investigated whether chronic administration of the selective nicotinic partial agonist varenicline improved motor, cognitive and affective symptoms in a transgenic mouse model of Huntington's disease...
December 23, 2016: Neuropharmacology
https://www.readbyqxmd.com/read/27986524/smoking-cessation-the-urgent-need-for-increased-utilization-of-varenicline
#16
EDITORIAL
Dianna Gaballa, Joanna Drowos, Charles H Hennekens
No abstract text is available yet for this article.
December 13, 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27971376/budgetary-impact-analysis-of-reimbursement-varenicline-in-the-smoking-cessation-treatment-of-patients-with-major-depression-in-spain
#17
S Cedillo, J Rejas
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27965778/the-management-of-asthmatic-smokers
#18
REVIEW
José Miguel Chatkin, Cynthia Rocha Dullius
Asthma is still a major public health problem in most countries; new strategies to better control this disease are necessary. Such strategies must include predisposing factors. One of these factors is smoking and a significant fraction of asthmatics are smokers. However, clinical trials studying new drugs or newer therapeutic regimens for asthma generally exclude smokers. Therefore, there is a lack of specific information about the treatment of asthma in smokers. The asthmatic smoker is a special phenotype with important therapeutic and prognostic clinical implications...
2016: Asthma research and practice
https://www.readbyqxmd.com/read/27956009/maintenance-pharmacotherapy-normalizes-the-relapse-curve-in-recently-abstinent-tobacco-smokers-with-schizophrenia-and-bipolar-disorder
#19
A Eden Evins, Susanne S Hoeppner, David A Schoenfeld, Bettina B Hoeppner, Corinne Cather, Gladys N Pachas, Kristina M Cieslak, Melissa Culhane Maravic
OBJECTIVE: To compare the effect of maintenance pharmacotherapy on sustained abstinence rates between recently abstinent smokers with schizophrenia and bipolar disorder (SBD) and general population smokers without psychiatric illness. METHOD: We performed a person-level, pooled analysis of two randomized controlled trials of maintenance varenicline, conducted in adult smokers with SBD and general population smokers, controlling for severity of dependence. Smokers abstinent after 12-weeks of open varenicline treatment were randomly assigned to ≥12-weeks maintenance varenicline or identical placebo...
December 9, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27940077/the-discriminative-stimulus-effects-of-i-v-nicotine-in-rhesus-monkeys-pharmacokinetics-and-apparent-pa2-analysis-with-dihydro-%C3%AE-erythroidine
#20
Megan J Moerke, Andy Z X Zhu, Rachel F Tyndale, Martin A Javors, Lance R McMahon
Quantitative analysis of antagonism is infrequently used to identify nAChRs mediating behavioral effects. Here, nicotine (0.032 mg/kg i.v.) was established as a discriminative stimulus in rhesus monkeys responding under a fixed ratio 5 schedule; pharmacokinetics and underlying nAChR mechanism(s) were examined. When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml...
December 8, 2016: Neuropharmacology
keyword
keyword
77072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"